2 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow ex vivo-expanded HER2-specific T cells: new trials by email Literature Review of ex vivo-expanded HER2-specific T cells trials Research Report on ex vivo-expanded HER2-specific T cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Withdrawn | University of Washington | 2012-06-01 | 2013-05-17 | |
| Vaccine Therapy in Treating Patients With Stage IV Breast Cancer HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 / Phase 2 | Completed | University of Washington | 23 | 2008-10-01 | 2017-05-25 |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox - HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | University of Washington | 8 | 2003-06-01 | 2014-11-11 |
Breast Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1)
United States (3)
Mary Disis (2) · Lupe Salazar (1)
R01CA129517 (1)